Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (191-200 of 261) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling InhibitionJohn D Martin, Ryan M Lanning, Vikash P Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Cancers|October 14, 2023
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular CarcinomaBetul Gok Yavuz, Saumil Datar, Shadi Chamseddine, et al.
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Medicine|August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastomaEudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Clinical and Translational Radiation Oncology|February 9, 2026
Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature reviewLara Caglayan, Oliver Blanck, Judit Boda-Heggemann, et al.
Journal of the National Cancer Institute|November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentVasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Pageof 27

Showing results (191-200 of 261) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling InhibitionJohn D Martin, Ryan M Lanning, Vikash P Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Cancers|October 14, 2023
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular CarcinomaBetul Gok Yavuz, Saumil Datar, Shadi Chamseddine, et al.
Nature Clinical Practice. Oncology|April 28, 2007
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancerChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Cancer Medicine|August 25, 2019
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastomaEudocia Q Lee, Alona Muzikansky, Dan G Duda, et al.
Future Oncology (London, England)|March 28, 2025
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, et al.
Journal of Neuro-Oncology|November 18, 2016
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastomaJayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, et al.
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Clinical and Translational Radiation Oncology|February 9, 2026
Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature reviewLara Caglayan, Oliver Blanck, Judit Boda-Heggemann, et al.
Journal of the National Cancer Institute|November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentVasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Pageof 27